PUBLISHER: The Insight Partners | PRODUCT CODE: 1567861
PUBLISHER: The Insight Partners | PRODUCT CODE: 1567861
The Asia Pacific upstream bioprocessing market was valued at US$ 1,976.10 million in 2022 and is expected to reach US$ 5,678.99 million by 2030; it is estimated to grow at a CAGR of 14.1% from 2022 to 2030.
Technological Advancements Boost Asia Pacific Upstream Bioprocessing Market.
The upstream bioprocessing market is experiencing a wave of technological advancements, presenting considerable industry opportunities. These advancements include innovative developments in cell culture systems, bioreactor design, process monitoring, and control, as well as the integration of automation and digitalization. In September 2023, Repligen Corporation and Sartorius introduced an integrated bioreactor system. Repligen's XCell Alternating Tangential Flow (ATF) upstream intensification technology has been integrated into the Sartorius Biostat stirred-tank reactor (STR). This bioreactor technology is designed to make the application of N perfusion and intensified seed train easier for biopharmaceutical firms. An embedded XCell ATF hardware and software module that combines integrated process analytical technologies with predefined advanced control recipes is incorporated into Biostat STR. This module is intended to simplify the management of cell growth and enhance cell retention in perfusion procedures, eliminating the need for a separate cell retention control tower. Such modern products feature enhanced process efficiency, scalability, and adaptability, which are crucial for meeting the evolving demands of biopharmaceutical production.
Advanced cell culture media formulations and next-generation bioreactor technologies are contributing to the optimization of upstream bioprocessing, in turn, enabling higher product yields, improved product quality, and the efficient production of complex biologics. The ongoing integration of advanced analytics and real-time process monitoring is revolutionizing data-driven decision-making in bioprocessing, driving precision and process optimization opportunities. Progress in biotechnology also fosters the development of flexible and modular manufacturing platforms. Additionally, the convergence of machine learning, artificial intelligence, and predictive analytics is paving the way for predictive bioprocessing, thereby unlocking proactive process control, quality assurance, and cost optimization opportunities. Thus, technological advancements in upstream bioprocessing are reshaping the industry, presenting new avenues for innovation, efficiency, and adaptability.
Asia Pacific Upstream Bioprocessing Market Overview
The Asia Pacific upstream bioprocessing market is segmented into China, Japan, Australia, India, South Korea, and the Rest of Asia Pacific. The market in this region is expected to grow at the highest CAGR during 2022-2030. China, India, and Japan are three major contributors to the growth of the market in Asia Pacific, which is mainly driven by rising demand for bioreactors as well as an increase in research centers and government funding. Moreover, many international market players are focusing on countries in Asia Pacific for geographic expansion and other strategies.
Asia Pacific Upstream Bioprocessing Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Upstream Bioprocessing Market Segmentation
The Asia Pacific upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country. Based on product type, the Asia Pacific upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters services held the largest market share in 2022.
Based on workflow, the Asia Pacific upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
Based on usage type, the Asia Pacific upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022.
Based on mode, the Asia Pacific upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house held a larger market share in 2022.
Based on country, the Asia Pacific upstream bioprocessing market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific upstream bioprocessing market share in 2022.
Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, and Entegris Inc are some of the leading companies operating in the Asia Pacific upstream bioprocessing market.